Romiplostim (Nplate®)
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)contractFind a Tender ↗Ref ocds-h6vhtk-0597b532014L0024active
Estimated value
—
goods
Awarded value
—
Suppliers
1
Lots
1
1 awarded
Published
10 Sept 2025
Description
Supply of Romiplostim (NPlate®) to NHS Scotland.
Scope
- Reference
- NP90925
- Commercial tool
- Standalone contract
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- Scotland
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| — | — | price | — |
Submission & procedure
- Procedure
- Negotiated without publication of a contract notice
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Awarded to
Awarded suppliers· 1 supplier
Awarded —
Award value
—
Other contracts from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Amgen Ltd· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| Ustekinumab | contract | — | 15 Jun 2026 |
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 | contract | — | 09 Jun 2026 |
| Transitional Drugs 7 | contract | — | 05 Jun 2026 |
| Transitional Drugs 6 | contract | — | 30 Mar 2026 |
| Transitional Drugs 6 | contract | — | 04 Feb 2026 |
| NP49425 Generic and Biosimilar Transition Medicines | contract | — | 19 Dec 2025 |
| NHS National Framework for Denosumab Injection commencing 1st January 2026 | contract | — | 04 Dec 2025 |
| Project/Contract NHS National Framework for Denosumab Injection | contract | — | 02 Oct 2025 |
| NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | contract | £47.0m | 29 Jul 2025 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | contract | — | 29 Jul 2025 |